NCT02740777View on ClinicalTrials.gov

Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

PHASE2CompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

July 31, 2019

Conditions
Human PapillomavirusCervical Intraepithelial NeoplasiaPersistent Infection
Interventions
BIOLOGICAL

HPV-16/18 vaccine

HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.

Trial Locations (2)

542699

Zhongshan Center for Disease Prevention and Control, Zhongshan

542899

Hezhou Center for Disease Prevention and Control, Hezhou

All Listed Sponsors
collaborator

Guangxi Center for Disease Control and Prevention

OTHER_GOV

lead

Shanghai Zerun Biotechnology Co.,Ltd

INDUSTRY

NCT02740777 - Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females | Biotech Hunter | Biotech Hunter